• Bazedoxifene as an IL-6/GP130 Pathway Inhibitor in Cancer Re

  2026-05-15

  This review explores the repositioning of bazedoxifene, a third-generation selective estrogen receptor modulator, as an inhibitor of the IL-6/GP130 signaling pathway in oncology. The paper synthesizes mechanistic evidence and preclinical findings, highlighting the compound’s dual role in estrogen receptor and cytokine signaling modulation for cancer therapy.

• HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus: Techni

  2026-05-15

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus addresses the need for reliable, high-yield synthesis of fluorescently labeled RNA probes for fluorescence-based detection, specifically in in situ hybridization (ISH) and Northern blot workflows. It is designed strictly for research use and should not be applied in diagnostic, clinical, or therapeutic workflows.

• Neuromedin S (rat): Technical Parameters and Workflow Guidan

  2026-05-14

  Neuromedin S (rat) provides a chemically defined, endogenous agonist for neuromedin U receptor signaling studies in rat-based GPCR/G protein research. This product is suitable for controlled laboratory workflows investigating energy homeostasis regulation, stress response, or circadian rhythm pathways, but is not intended for diagnostic or therapeutic applications.

• MDV3100 (Enzalutamide): Decoding AR Heterogeneity in Prostat

  2026-05-14

  Explore how MDV3100 (Enzalutamide) enables advanced research into androgen receptor heterogeneity and therapy response in prostate cancer. This article uniquely analyzes the impact of AR signaling diversity on experimental design and mechanistic discovery.

• Carboplatin in Cancer Research: Mitochondrial Metabolism and

  2026-05-13

  Explore the role of Carboplatin, a platinum-based DNA synthesis inhibitor, in cutting-edge cancer research. This article uniquely bridges preclinical oncology with emerging insights into mitochondrial metabolism, offering advanced assay guidance.

• Itraconazole: Triazole Antifungal Agent in Candida Biofilm R

  2026-05-13

  Itraconazole stands at the forefront of antifungal research, enabling precise interrogation of Candida biofilm resistance and drug interactions. By leveraging APExBIO’s validated Itraconazole, researchers can dissect autophagy-driven resistance mechanisms and optimize workflows for advanced fungal infection models.

• RITA (NSC 652287): Mechanistic Mastery and Translational Str

  2026-05-12

  This thought-leadership article explores how RITA (NSC 652287), a potent MDM2-p53 interaction inhibitor, empowers translational researchers to accelerate breakthroughs in cancer biology. By weaving mechanistic insights with evidence-based experimental and strategic guidance, it contextualizes RITA’s unique attributes—selective cytotoxicity, robust in vivo performance, and workflow-anchored reliability—within the evolving landscape of anti-cancer drug evaluation. The article also integrates contemporary scholarship to refine in vitro assay design and positions RITA as an advanced tool for elucidating p53-mediated responses, while differentiating itself from conventional product overviews by focusing on actionable scientific strategy.

• Tetraethylammonium Chloride: Optimizing K+ Channel Assays

  2026-05-12

  Tetraethylammonium chloride (TEAC) from APExBIO sets the benchmark for reproducible potassium channel inhibition, enabling researchers to dissect ion conduction and vascular mechanisms with high precision. This guide translates recent experimental breakthroughs and troubleshooting strategies into actionable protocols for vascular, neural, and metabolic research.

• Decoding Ferroptosis: ECL Kits Power Translational Oncology

  2026-05-11

  This thought-leadership article explores how the APExBIO ECL Chemiluminescent Substrate Detection Kit advances mechanistic studies of ferroptosis and immune modulation in gastric cancer, as illustrated by recent carbon-ion radiotherapy research. Blending mechanistic clarity with strategic workflow advice, it guides translational researchers on leveraging chemiluminescent Western blotting to accelerate discovery and reproducibility in oncology.

• Lactate-GPR81/Rac1 Axis Enables Insulin-Independent Glucose

  2026-05-11

  This study reveals that L-lactate activates the GPR81/FARP1/Rac1 pathway, triggering GLUT4 translocation and glucose uptake in skeletal muscle independently of insulin. The findings highlight a metabolite-driven mechanism underlying exercise-induced metabolic control, suggesting novel targets for hyperglycemia intervention.

• Optimizing Cell Assays with EZ Cap™ Cy5 Firefly Luciferase m

  2026-05-10

  This article provides a rigorous, scenario-based analysis of how EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP, SKU R1010) advances cell viability and transfection workflows. Drawing on validated protocols and recent literature, we explore real laboratory challenges and demonstrate how R1010 delivers reproducible, dual-mode detection, and reliable translation outcomes for biomedical researchers.

• GW4064 in FXR Signaling: Pioneering Assay Design and Cellula

  2026-05-09

  Explore how GW4064, a potent non-steroidal FXR agonist, advances metabolic research through precise FXR activation. This article uniquely bridges mechanistic insight with practical assay parameters, enabling robust, reproducible study design.

• Neuroligin 1, Striatal D2-MSNs, and PKC in Autistic-Like Beh

  2026-05-09

  This study uncovers how Neuroligin 1 deletion in striatal D2-expressing medium spiny neurons leads to hyperactivation, driving excessive repetitive behaviors characteristic of autism spectrum disorder. Single-nucleus RNA sequencing and protein assays further reveal protein kinase C overactivation as a mechanistic link, offering new targets for intervention.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-05-08

  Schwartz's dissertation critically evaluates how in vitro assays measure anti-cancer drug effects, distinguishing between proliferation inhibition and cell death. This nuanced approach has practical implications for interpreting the efficacy of apoptosis inhibitors, such as survivin-targeting compounds, in preclinical cancer models.

• MLN4924 HCl Salt: Strategic Horizons in Neddylation Inhibiti

  2026-05-07

  This thought-leadership article explores the mechanistic and translational significance of MLN4924 HCl salt, a potent NEDD8-activating enzyme inhibitor, for researchers targeting ubiquitin-proteasome pathways in oncology and virology. Integrating recent evidence on viral immune evasion, cell death modulation, and workflow optimization, the article provides actionable guidance and competitive context, while highlighting cross-domain opportunities and future directions.

451 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page